SavedAdd your journal

Journals / Bozok Tıp Dergisi / 2014 / Cilt: 4 - Sayı: 3

FDG PET in the Follow-up of Medullary Thyroid Carcinoma Patients

MEDÜLLER TİROİD KARSİNOMALI HASTALARIN TAKİBİNDE FDG PET

Y. Zeki ÇELEN
Ebuzer KALENDER
Hasan Deniz DEMİR
Hüseyin KARAOĞLAN
Umut ELBOĞA
Ertan ŞAHİN
Pages
14–18
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also allowing to whole body imaging is a significant advantage of it.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of study is to evaluate the impact of fluorodeoxyglucose positron emission tomography(FDG PET) in the follow-up of medullary thyroid carcionma (MTC) patients who had elevated calcitonin levelsafter surgery.Materials and Methods: Six patients diagnosed with MTC who referred to our clinic for FDG PET imagingbecause of the elevated calcitonin levels were included.
📊
Key Findings & Data:Mean age was 52±8 years.Results: In 4 patients whose calcitonin levels were 75 pg/ml, 90pg/ml, 94 pg/ml and 127 pg/ml respectively,there was no evidence for recurrence or metastasis of MTC on FDG PET.
💡
Conclusion & Impact:Also allowing to whole body imaging is a significant advantage of it.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of study is to evaluate the impact of fluorodeoxyglucose positron emission tomography(FDG PET) in the follow-up of medullary thyroid carcionma (MTC) patients who had elevated calcitonin levelsafter surgery.Materials and Methods: Six patients diagnosed with MTC who referred to our clinic for FDG PET imagingbecause of the elevated calcitonin levels were included. All were male. Mean age was 52±8 years.Results: In 4 patients whose calcitonin levels were 75 pg/ml, 90pg/ml, 94 pg/ml and 127 pg/ml respectively,there was no evidence for recurrence or metastasis of MTC on FDG PET. FDG PET findings were positive in 2patients whose calcitonin levels were 1300 pg/ml and 2110 pg/ml respectively. In these patients lymph nodemetastases and bone metastases were detected.Conclusion: It seems that there is no place to FDG PET for routine imaging of MTC. But here calcitonin levels areimportant. In patients who have calcitonin levels higher than 1000 pg/ml FDG PET can be very useful and detecta lot of lesion foci. Also allowing to whole body imaging is a significant advantage of it.

Özet

Amaç: Çalışmanın amacı cerrahi sonrası yüksek kalsitonin seviyelerine sahip medüller tiroid karsinomlu (MTK)hastaların takibinde florodeoksiglikoz pozitron emisyon tomografisinin (FDG PET) etkinliğini değerlendirmektedir.Gereç ve Yöntemler: Çalışmaya yüksek kalsitonin seviyeleri nedeniyle kliniğimize FDG PET görüntüleme içinyönlendirilen MTK tanılı 6 hasta dahil edildi. Bütün hastalar erkekti. Yaş ortalaması 52±8 idi.Bulgular: Kalsitonin seviyeleri sırasıyla75 pg/ml, 90pg/ml, 94 pg/ml ve 127 pg/ml olan 4 hastada FDG PETgörüntülemede MTKnın rekürrens ya da metastazını düşündürecek bulgu izlenmedi. Kalsitonin seviyeleri1300 pg/ml ve 2110 pg/ml olan 2 hastada ise FDG PET bulguları pozitifti. Bu hastalarda lenf nodu ve kemikmetastazları saptandı.Tartışma: Öyle görünüyor ki MTKnın rutin görüntülemesinde FDG PETe yer yoktur. Ancak burada kalsitoninseviyeleri önem arz etmektedir. Kalsitonin seviyeleri 1000 pg/mlden yüksek hastalarda FDG PET oldukça faydalıolabilmekte ve birçok lezyon odağını tespit edebilmektedir. Ayrıca tüm vücut görüntülemeye olanak sağlamasıda önemli bir avantajıdır.

🔖

Cite This Article

ÇELEN, Y. Z., KALENDER, E., DEMİR, H. D., KARAOĞLAN, H., ELBOĞA, U., ŞAHİN, E. (2022). FDG PET in the Follow-up of Medullary Thyroid Carcinoma Patients. Bozok Tıp Dergisi, Cilt: 4 - Sayı: 3, 14–18. https://ajindex.com/articles/468972

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91(9):1797–808
  2. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299–310
  3. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Non parallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):278–85
  4. Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol. 2005;89(3):122–9
  5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S, 1985-1995. Cancer. 1998;83(12):2638–48
  6. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol. 1991;7(2):92–9
  7. Bergholm U, Adami HO, Bergström R, Johansson H, Lundell G, Telenius-Berg M, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer. 1989;63(6):1196–204
  8. Pitt SC, Moley JF. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol. 2010;37(6):567-79
  9. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–48
  10. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M,et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):501–7
  11. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005;12(4):254–60
  12. Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 2008;33(2):67–73
  13. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27(5):490–6
  14. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emissio